Page last updated: 2024-12-04

indoleglycerol phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

indoleglycerol phosphate: inducer of tryptophan synthase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate : The (1S,2R)-diastereomer of 1-C-(indol-3-yl)glycerol 3-phosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID444150
CHEBI ID51793
MeSH IDM0051693

Synonyms (11)

Synonym
indoleglycerol phosphate
(3-indolyl)-glycerol phosphate
indole-3-glycerol phosphate
C03506
(1s,2r)-1-c-(indol-3-yl)glycerol 3-phosphate
DB04143
CHEBI:51793
(2r,3s)-2,3-dihydroxy-3-(1h-indol-3-yl)propyl dihydrogen phosphate
[(2r,3s)-2,3-dihydroxy-3-(1h-indol-3-yl)propyl] dihydrogen phosphate
Q27094983
DTXSID501344224
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1-C-(indol-3-yl)glycerol 3-phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
IAA biosynthesis I025

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (16.28)18.7374
1990's17 (39.53)18.2507
2000's11 (25.58)29.6817
2010's5 (11.63)24.3611
2020's3 (6.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other42 (97.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]